The Impact of Primary Antiphospholipid Syndrome on Long-term Cardiovascular Outcomes After Percutaneous Coronary Intervention and Stenting in Patients With Myocardial Infarction

    loading  Checking for direct PDF access through Ovid


To the Editor:
Primary antiphospholipid syndrome is an autoimmune disease characterized by recurrent vascular thrombosis and pregnancy-related morbidity due to circulating antiphospholipid (aPL) antibodies, including lupus anticoagulant (LA), anticardiolipins (aCLs), and anti-β2 glycoprotein I (anti-β2GPI) antibodies.1 Patients with APS are at risk of developing accelerated atherosclerosis and early coronary artery disease (CAD), which may ultimately lead to increased occurrence of acute coronary syndrome (ACS).2 Percutaneous coronary intervention with stent placement is the current mainstay of therapy in patients with MI, and some studies have suggested that circulating aPL antibodies may increase the risk of in-stent stenosis and thrombosis.3,4 In parallel, little is known about the long-term outcome in patients with PAPS undergoing PCI and stenting, and most of the information available comes from patients with APS overlapping systemic lupus erythematosus (SLE) instead of individuals with the primary forms of the syndrome.5
This nested case-control study was aimed to evaluate the short- and long-term occurrence of MACEs in patients with PAPS undergoing PCI and stenting after MI.

Related Topics

    loading  Loading Related Articles